Table 4.
SRD | Predicted aided AzBio† |
Candidacy prediction‡ |
Clinical aided AzBio |
Clinical Candidacy |
||
---|---|---|---|---|---|---|
S123 (L) | 1.2 | > 0.845* | 58% | No | N/Aǂ | No |
S123 (R) | 1.58 | < 0.845* | 79% | 92% | ||
S124 (L) | 0.76 | < 0.845* | 35% | Yes | 1% | Yes |
S124 (R) | 0.43 | < 0.845* | 17% | 16% | ||
S125 (L) | 0.62 | < 0.845* | 27% | Yes | 36% | Yes |
S125 (R) | 0.28 | < 0.845* | 9% | 7% | ||
S126 (L) | 0.29 | < 0.845* | 10% | Yes | 11% | Yes |
S126 (R) | 0.33 | > 0.845* | 12% | 9% |
The optimal cutoff estimated using the ROC curve
AzBio scores were predicted using Eq. 3.
When the predicted AzBio scores or the optimal SRD cutoff value was used, the same prediction was shown.
S123 did not complete the AzBio sentence test for his right ear due to participation schedule constraints.